A public change to healthier lifestyles with more physical activity and better nutrition, including caloric restriction, is required to address the obesity epidemic. Weight loss can be achieved by caloric restrictions; current research suggests that this may be achieved by consumption of slowly absorbed carbohydrates owing to the resulting prolonged satiety. Our rationale was to prolong the satiety of overweight volunteers by supplementation with a proprietary formulation Glucaffect™ which delays absorption of carbohydrates. Glucaffect™ provides potent a-glucosidase inhibitors of herbal source such Pycnogenol® , Madeglucyl™ and various others which obstruct absorption of carbohydrates, such as starch. Fifty overweight subjects received either Glucaffect™ or an inactive control product for eight weeks. Consumption of Glucaffect™ was found to statistically significantly lower blood-fasting glucose from baseline 145.3 mg/dL to 101.1 mg/dL (-30.4%) and Hba1c from 7.59% to 6.33% as compared to the control group where values decreased only marginally. The weight and the body mass index (BMI) decreased significantly from an average of 88.5 kg (BMI 26.8 kg/m2) to 81.3 kg (BMI 24.5 kg/m2) as compared to the control group. In conclusion, Glucaffect™ enabled subjects with metabolic syndrome to achieve healthy BMI and blood glucose levels. Glucaffect™ was well tolerated and no subject dropped out. Copyright © 2009 John Wiley & Sons, Ltd.

Daily consumption of reliv glucaffect™ for 8 weeks significantly lowered blood glucose and body weight in 50 subjects

LEDDA, ANDREA FRANCESCO;Vinciguerra, G.;
2009-01-01

Abstract

A public change to healthier lifestyles with more physical activity and better nutrition, including caloric restriction, is required to address the obesity epidemic. Weight loss can be achieved by caloric restrictions; current research suggests that this may be achieved by consumption of slowly absorbed carbohydrates owing to the resulting prolonged satiety. Our rationale was to prolong the satiety of overweight volunteers by supplementation with a proprietary formulation Glucaffect™ which delays absorption of carbohydrates. Glucaffect™ provides potent a-glucosidase inhibitors of herbal source such Pycnogenol® , Madeglucyl™ and various others which obstruct absorption of carbohydrates, such as starch. Fifty overweight subjects received either Glucaffect™ or an inactive control product for eight weeks. Consumption of Glucaffect™ was found to statistically significantly lower blood-fasting glucose from baseline 145.3 mg/dL to 101.1 mg/dL (-30.4%) and Hba1c from 7.59% to 6.33% as compared to the control group where values decreased only marginally. The weight and the body mass index (BMI) decreased significantly from an average of 88.5 kg (BMI 26.8 kg/m2) to 81.3 kg (BMI 24.5 kg/m2) as compared to the control group. In conclusion, Glucaffect™ enabled subjects with metabolic syndrome to achieve healthy BMI and blood glucose levels. Glucaffect™ was well tolerated and no subject dropped out. Copyright © 2009 John Wiley & Sons, Ltd.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11697/123091
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact